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ABSTRACT
The proteasome inhibitor bortezomib is a new targeted treatment option for 
refractory or relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited 
efficacy of bortezomib alone has been reported. A terminal pro-apoptotic endoplasmic 
reticulum (ER) stress/unfolded protein response (UPR) is one of the several 
mechanisms of bortezomib-induced apoptosis. Recently, it has been documented 
that UPR disruption could be considered a selective anti-leukemia therapy. CX-
4945, a potent casein kinase (CK) 2 inhibitor, has been found to induce apoptotic 
cell death in T-ALL preclinical models, via perturbation of ER/UPR pathway. In this 
study, we analyzed in T- and B-ALL preclinical settings, the molecular mechanisms of 
synergistic apoptotic effects observed after bortezomib/CX-4945 combined treatment. 
We demonstrated that, adding CX-4945 after bortezomib treatment, prevented 
leukemic cells from engaging a functional UPR in order to buffer the bortezomib-
mediated proteotoxic stress in ER lumen. We documented that the combined 
treatment decreased pro-survival ER chaperon BIP/Grp78 expression, via reduction 
of chaperoning activity of Hsp90. Bortezomib/CX-4945 treatment inhibited NF-κB 
signaling in T-ALL cell lines and primary cells from T-ALL patients, but, intriguingly, in 
B-ALL cells the drug combination activated NF-κB p65 pro-apoptotic functions. In fact 
in B-cells, the combined treatment induced p65-HDAC1 association with consequent 
repression of the anti-apoptotic target genes, Bcl-xL and XIAP. Exposure to NEMO 
(IKKγ)-binding domain inhibitor peptide reduced the cytotoxic effects of bortezomib/
CX-4945 treatment. Overall, our findings demonstrated that CK2 inhibition could be 




Acute lymphoblastic leukemia (ALL) is a malignant 
disorder that originates from hematopoietic precursors 
committed to either T- or B-cell lineage. T-ALL comprises 
15-20% of ALL cases, whereas B-ALL represents 80-
85% [1]. Overall, ALL is the most common pediatric 
malignancy [2]. ALL survival rates have improved 
especially in children, due to the recognition of the 
biologic heterogeneity of ALL, the utilization of risk-
adapted therapy, and the development of protocols with 
optimized chemotherapy combinations. However, relapsed 
ALL is difficult to treat [3]. Therapy for relapsed pediatric 
ALL is hindered by low remission rates and high toxicity, 
especially in second and subsequent relapses within 
three years of diagnosis [4-6]. Therapeutic alternatives 
with effective anti-leukemic potential and lower toxicity 
profile are needed for these extensively pretreated patients. 
Currently, several new treatment options for relapsed 
ALL have emerged, including deoxyadenosine analogs 
(clofarabine and nelarabine), monoclonal antibodies 
(alemtuzumab and epratuzumab), and the proteasome 
inhibitor, bortezomib [3, 7].
Bortezomib (Velcade, formerly PS-341) is the 
first proteasome inhibitor approved by the U.S. FDA for 
multiple myeloma (MM) [8, 9], and, more recently, for 
relapsed mantle cell lymphoma (MCL) treatment [10]. 
Bortezomib is a dipeptidyl boronic acid analog that 
reversibly inhibits the 26S proteasome. The proteasome 
has been successfully targeted for the treatment of MM and 
MCL but, in other hematologic malignancies, bortezomib 
has been less effective as a single agent. However, phase 
I studies of Children’s Oncology Group and Pediatric 
Preclinical Testing Program have demonstrated that, 
in refractory and/or relapsed ALL, bortezomib could 
act as a chemosensitizing agent [11-13]. In particular, 
the Therapeutic Advances in Childhood Leukemia 
& Lymphoma (TACL) phase I and II studies have 
documented that bortezomib is able to restore sensitivity 
of leukemic cells to conventional dexamethasone, 
asparaginase, vincristine, doxorubicin, and cytarabine 
chemotherapy [14]. Moreover, about twenty therapeutic 
targeted small molecules are currently being assessed in 
combination with bortezomib in more than 40 ongoing 
early-phase clinical trials. The majority of the studies are 
evaluating patients with hematologic malignancies and 
have demonstrated that bortezomib displays an excellent 
synergistic activity with deacetylase inhibitors [15], kinase 
inhibitors [16, 17], and endoplasmic reticulum (ER) stress 
modulators [18, 19]. 
Bortezomib molecular mechanisms of action in ALL 
are still not completely understood. Previous reports have 
highlighted that, in most cases, it could affect activation 
of the NF-κB pathway through IκBα stabilization [20, 
21], but it also up-regulated NF-κB activity [22]. In MM 
cells, it has been shown that a terminal pro-apoptotic ER 
stress/UPR elicitation is involved in bortezomib-induced 
cytotoxicity [23]. Interestingly, ER stress/UPR signaling is 
recently gaining increasing recognition as a key targetable 
pathway in ALL [24-27]. 
CX-4945 is a potent and selective small molecule 
inhibitor of the casein kinase 2 (CK2), currently used 
in phase I clinical trial in patients with advanced 
solid cancers (NCT00891280) and in MM patients 
(NCT01199718). CK2 is a pivotal pro-survival protein 
kinase that creates a cellular environment positive to 
neoplastic cells by phosphorylating an impressive number 
of substrates [28]. CK2 targets IKK/NF-κB signaling [28-
30], the Akt pathway [31], and the ER stress/UPR axis 
[26, 32, 33]. We have recently demonstrated that CK2 
inhibition by CX-4945 potently down-regulated UPR 
signaling in T-ALL preclinical models [26]. Recently, the 
efficacy of a bortezomib/CX-4945 combination has been 
described in a study on MM and MCL cells [34]. In the 
present work, we explored the synergistic cytotoxic effects 
of a bortezomib/CX-4945 combination in a panel of T- and 
B-ALL cell lines and lymphoblasts from T- and B-ALL 
patients. Our starting hypothesis was that adding CX-4945 
to leukemic cells previously exposed to bortezomib, could 
prevent cancer cells from engaging the UPR in order to 
effectively buffer the increased proteotoxic load in the 
ER lumen, thus enhancing sensitivity to the proteasome 
inhibitor. Bortezomib-induced apoptotic effects were 
significantly amplified by CK2 inhibition and apoptotic 
cell death was accompanied by down-regulation of ER 
stress/UPR signaling. Exposure to combined treatment 
provoked a reduction of pro-survival ER chaperon BIP/
Grp78 expression, the main activator of the UPR and 
a well-known facilitator of tumor cell evasion from 
chemotherapeutics. We also demonstrated that modulation 
of NF-κB pathway was involved in bortezomib/CX-4945 
mechanisms of action. However, in B-ALL cell lines and 
patient lymphoblasts, the drug combination was able to 
unleash NF-κB pro-apoptotic ability. Overall, our findings 
provided a rationale for the use of CK2 inhibitors in 
bortezomib-based combination protocols in ALL.
RESULTS
A bortezomib/CX-4945 combined treatment 
induces synergistic apoptotic effects in T- and 
B-ALL cell lines
We investigated whether CK2 and proteasome 
inhibition could cause synergistic effects in terms of 
reduced cell viability in ALL models. To this end, T- 
(MOLT-4, JURKAT, CEM-R) and B- (KOPN-8, RS4;11, 
NALM-6) ALL cell lines were incubated for 46 h total 
with either one drug alone or with a combination (6 h 
of pre-treatment with bortezomib, followed by adding 
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of CX-4945 for 40 h) of two drugs at a constant ratio 
of 1:2000 (bortezomib:CX). Cell viability rates and 
C.I.s were then calculated. The combined treatment was 
strongly synergistic, as indicated by C.I.s well below 1, 
except for some CIs of CEM-R and NALM-6 cells (Figure 
1A). Notably, synergistic effects were not observed after 
simultaneous combined treatment with bortezomib and 
CX-4945 (data not shown). To further evaluate whether 
the observed effects of bortezomib/CX-4945 treatment on 
cell viability could be related to apoptosis, flow cytometry 
analysis was performed. Cells were treated for 24 h with 
bortezomib (2.5 nM) and CX-4945 (5 µM) either alone 
or in combination (6 h of pre-treatment with bortezomib, 
followed by adding of CX-4945 for 18 h). We detected 
a statistically significant increase in the percentage of 
early apoptotic (single positive for Annexin V) and/or late 
apoptotic (double positive for Annexin V and PI) cells 
after drug combination treatment as compared with single 
treatments, especially in MOLT-4, KOPN-8 and RS4;11 
cell lines (Figure 1B).
Apoptosis induced by the bortezomib/CX-4945 
combination has mitochondrial and ER-stress 
implications
Apoptosis induction was further assessed by 
western blot analysis of caspase-8, caspase-3 and poly 
(ADP-ribose) polymerase (PARP) cleavage. The drug 
combination was able to induce a more significant time-
dependent cleavage of the three proteins, compared to 
single agent treatment. The time of maximum cleavage 
was different, depending on the cell line (Figure 2A). 
Cleaved PARP was quantified using densitometry 
scanning and results were showed as Relative Induction 
values (Rel.Ind.), the amount of protein present in treated 
samples relative to untreated cells after normalizing 
to actin band density. Given the roles played by both 
bortezomib [23, 35] and CX-4945 [26, 32] in ER stress/
UPR mechanisms, we also analyzed in MOLT-4, KOPN-
8 and RS4;11 cells, caspase-4 cleavage, a known marker 
of ER stress [36]. After 16 h of treatment, the drug 
combination caused a more marked cleavage than single 
drugs (Figure 2A). Mitochondrial involvement was also 
investigated through western blot analysis of Bcl-2 family 
members expression. As shown in Figure 2B, bortezomib/
CX-4945 combination caused a time-dependent reduction 
of anti-apoptotic Bcl-2, Bcl-XL and Mcl1 as compared 
with single treatments, to a different extent depending on 
the cell line. In particular, in T-ALL cells and in NALM-6 
cells, Bcl-2 down-modulation occurred already after 6 h 
of treatment, while in KOPN-8 and RS4;11 the decrease 
was detected after 24 h of treatment. Bcl-XL decreased 
already after 6 h in all cell lines. The same occurred for 
Mcl1 expression, except in JURKAT cells where, after 6 
h of combined treatment, Mcl1 level increased and then 
decreased at 16 and 24 h, as confirmed by Rel.Ind. values. 
Pro-apoptotic Bax accumulation could be observed after 
24 h of combined treatment, while Bak increase occurred 
earlier, already after 6 h of treatment. To better analyze 
mitochondrial involvement, we studied mitochondrial 
membrane potential by flow cytometry analysis of JC-1 
dye [37] in RS4;11 cell line. As shown in Supplementary 
Figure S1, after 16 h of treatment, the drug combination 
was able to diminish red JC-1 fluorescence more than 
single treatments. Taken together, our findings indicated 
that bortezomib and CX-4945 cooperated to induce 
apoptotic cell death in ALL cells. Disrupted balance of 
Bcl-2 family members, mitochondrial depolarization and 
caspase-4 cleavage suggested the involvement of both 
mitochondrial and ER-stress mechanisms, respectively. 
The cleavage of caspase-8 could suggest the involvement 
of death receptor mechanism, therefore this pathway needs 
to be studied in more depth. 
Bortezomib/CX-4945 combination affects ER 
stress/UPR signaling
It is emerging that down-regulation of UPR 
signaling pathway drives apoptotic cell death also in pre-
clinical settings of T-ALL [24, 26]. In contrast, bortezomib, 
causing ER lumen overload, is known to potently induce 
ER stress response [23, 36]. To better understand the 
molecular determinants of apoptosis induced by such 
opposing stimuli in ALL cell lines, we studied by western 
blot analysis the effects of bortezomib/CX-4945 combined 
treatment on ER stress/UPR markers expression. 
Regarding BIP/Grp78, a well-known mediator of the UPR 
pro-survival arm [38], we found that CX-4945 caused a 
time-dependent decrease of protein expression in all cell 
lines, whereas bortezomib rather induced an increase in 
almost all cell lines (MOLT-4 and CEM-R at 6 h, KOPN-
8 and RS4;11 at all times of treatment, NALM-6 at 24 h) 
(Figure 3A). Intriguingly in combination with bortezomib, 
CX-4945 was able to overcome the opposite effect of the 
proteasome inhibitor, that reportedly is strongly correlated 
to resistance to bortezomib [18], leading to a stronger and 
more lasting BIP/Grp78 decrease. Densitometry analysis 
confirmed these observations (Figure 3A). In contrast, the 
expression of IRE1α, CHOP, Thr980 p-PERK and Ser51 
p-EIF2α increased, to a different extent depending on 
the cell line, after exposure to CX-4945 and bortezomib 
as single treatments. This indicated for both drugs a 
concomitant induction of a significant stress in the ER 
lumen, as IRE1α, CHOP, p-PERK and p-EIF2α are 
well-established markers of ER stress/UPR-mediated 
apoptosis [39]. However, the combined treatment was able 
to induce an enhancement of the levels of these markers 
more markedly than single drugs, within the 24 h of 
treatment (Figure 3A). Therefore, our data suggested that 
sequential adding of CX-4945 after a previous exposure 
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Figure 1: Bortezomib/CX-4945 combination induces synergistic apoptotic effects in T- and B-ALL cell lines. A. MTT 
assays of T-ALL and B-ALL cell lines treated for a total of 46 h with either one drug alone or with a combination (6 h of pre-treatment with 
bortezomib, followed by adding of CX-4945 for 40 h) of two drugs at a constant ratio of 1:2000 (bortezomib:CX-4945). The combined 
treatments resulted in a strong synergism (CIs 0.1-0.3), synergism (CIs 0.3-0.7), or moderate/slight synergism (CIs 0.7-0.9); data are 
representative of three independent experiments bars, s.d. CX, CX-4945; BZ, bortezomib. B. Flow cytometric analysis of Annexin V-FITC/
PI-stained T-ALL and B-ALL cells treated for 24 h with CX-4945 (5 µM) and bortezomib (2.5 nM) either alone or in combination (6 h of 
pre-treatment with bortezomib, followed by adding of CX-4945 for 18 h). A significant increase in apoptotic cells is documented in samples 
treated with the drug combination with respect to single treatments. Asterisks indicate statistically significant differences (*P < 0.05; **P < 
0.005; ***P < 0.0005). Results are the mean of three different experiments ±s.d. Ctrl, untreated cells; CX+BZ, drug combination.
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to bortezomib, could prevent ALL cells from buffering 
a stressed, overloaded ER lumen with a functional UPR, 
thus leading cells to apoptotic death more efficiently as 
compared with single agents. It has been reported [40] 
in MCL patient cells and in a mouse model of MCL 
xenotransplantation, that BIP/Grp78 depletion via its 
dissociation from Hsp90/BIP complexes led to inhibition 
of UPR and to apoptosis. Moreover, it is well known 
that CK2 inhibition, through dephosphorylation of Ser13 
p-Cdc37, a Hsp90 co-chaperone, is able to impair Hsp90 
activity [33]. To understand if BIP/Grp78 depletion, 
observed after the bortezomib/CX-4945 combined 
treatment, could be related to an impairment of the BIP/
Hsp90/Cdc37 complex, we immunoprecipitated Hsp90 
and we analyzed, by western blot, its association with 
BIP/Grp78 and Cdc37. In both MOLT-4 and RS4;11 cells, 
the combined treatment inhibited the interactions between 
Hsp90 and BIP/Grp78 more effectively than CX-4945 
single treatment and to the same extent as tanespimycin 
(17-AAG), a specific Hsp90 inhibitor (Figure 3B). In 
contrast, bortezomib alone increased the association 
between Hsp90 and BIP/Grp78, as previously reported 
[18]. The levels of Cdc37 immunoprecipitated with 
Hsp90 followed the same trend of BIP/Grp78. Finally, 
western blot analysis of Ser13 p-Cdc37 levels confirmed 
that CX-4945, alone and in combination with bortezomib, 
through inhibition of Cdc37 phosphorylation, may drive 
the impairment of Hsp90 activity, leading to Hsp90/
BIP dissociation, BIP/Grp78 depletion, and consequent 
inhibition of UPR. Densitometry analysis gives a 
quantitative support to these observations. 
A bortezomib/CX-4945 combined treatment 
affects STAT3 phosphorylation and NF-κB 
activation
Both CK2 and proteasome inhibitions result in 
inactivation of the STAT3 and NF-κB survival pathways 
[41]. We analyzed the effects of CX-4945, bortezomib, 
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and the combination of the two drugs on STAT3 and NF-
κB p65 phosphorylation in ALL cell lines. Western blot 
analysis documented that CK2 inhibition by CX-4945 
caused a reduction in Ser727 p-STAT3 (a known target 
of CK2 dependent phosphorylation) and also in Tyr705 
p-STAT3 levels and this inhibition was potentiated after 
the exposure to the drug combination (Figure 4A). This 
finding correlates with previous observations obtained 
in MM and MCL preclinical settings [34]. Levels of 
Ser529 p-NF-κB, another known target site of CK2-
dependent phosphorylation, decreased, as expected, 
in a time-dependent manner after CX-4945 exposure. 
Bortezomib increased phosphorylation at this residue 
(except for RS4;11 cells) but, intriguingly, the combined 
treatment within 24 h down-regulated Ser529 p-NF-κB 
more efficiently than CX-4945 alone, in all ALL cell lines 
(Figure 4B). Ser536 p-NF-κB levels displayed a different 
trend. In T-ALL cell lines (MOLT-4 and JURKAT) we 
observed a reduction of Ser536 phosphorylation after the 
combined treatment, with respect to single agents, while 
in B-ALL cell lines (KOPN-8 and RS4;11), Ser536 p-NF-
κB was markedly induced by the bortezomib/CX-4945 
Figure 2: Apoptosis induced by the bortezomib/CX-4945 combination involves both mitochondrial and ER-stress A. 
Western blot analysis documenting a time-dependent cleavage of caspase-8, caspase-3, PARP and caspase-4. Densitometry scanning of 
cleaved PARP bands was performed. β-actin bands are not shown here, but are shown in B. B. Time-dependent modulation of Bcl-2 family 
members expression by CX-4945 (5 µM) and bortezomib (2.5 nM) either alone or in combination (6 h of pre-treatment with bortezomib, 
followed by adding of CX-4945 for 6, 16 and 24 h). Fifty μg of protein was blotted to each lane. Antibody to β-actin served as a loading 
control. Molecular weights are indicated at right. The Relative Induction (Rel.Ind.) is the amount of protein present in treated samples 
relative to untreated cells after normalizing to β-actin density. 
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combination (Figure 4B). Moreover, in T-ALL cell lines 
dephosphorylation of Ser536 p-NF-κB correlated with 
dephosphorylation of its inhibitor IκBα at Ser32/36 and 
with the increase in total levels of IκBα. Also in B-ALL 
cell lines, western blot analysis demonstrated a correlation 
between the increase in Ser536 p-NF-κB, induction of 
Ser32/36 p-IκBα, and reduction of total levels of IκBα. 
These differences in NF-κB phosphorylation were 
confirmed by immunofluorescence analysis of Ser536 
p-NF-κB nuclear localization. Figure 4C shows that, in 
MOLT-4 cells, the bortezomib/CX-4945 combination did 
not induce Ser536 p-NF-κB nuclear translocation, whereas 
in RS4;11 cells the combined treatment caused a nuclear 
accumulation of Ser536 p-NF-κB. Taken together, these 
results indicate that in T-ALL cell lines the bortezomib/
CX-4945 combination induced an inhibition of the NF-κB 
pathway, whereas in B-ALL cells, the combined treatment 
triggered NF-κB signaling activation.
Bortezomib/CX-4945 combined treatment induces 
NF-κB pro-apoptotic activation in the RS4;11 cell 
line
NF-κB activation observed in RS4;11 cells does 
not correlate with a lower sensitivity of this cell line to 
the bortezomib/CX-4945 combination, as indicated by 
MTT assays and apoptosis analysis. NF-κB is generally 
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Figure 3: Bortezomib/CX-4945 combination modulates ER stress/UPR signaling in T- and B-ALL cell lines. BIP/Grp78 
depletion is provoked by impairment of Hsp90 chaperoning activity A. Western blot analysis documenting the time-dependent modulation 
of ER stress/UPR signaling markers induced by CX-4945 (5 µM) and bortezomib (2.5 nM) either alone or in combination (6 h of pre-
treatment with bortezomib, followed by adding of CX-4945 for 6, 16 and 24 h). Fifty μg of protein was blotted to each lane. Antibody 
to β-actin served as a loading control. Molecular weights are indicated at right. Ser51 p-EIF2α Relative Induction values (Rel.Ind.) were 
obtained by normalizing to EIF2α density. Ba. Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) 
and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 µM) and bortezomib (2.5 nM) either alone or in combination (6 h of pre-treatment 
with bortezomib, followed by adding of CX-4945 for 16 h). 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody 
and then analyzed with the indicated antibodies. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 
Bb. Western blot analysis of Ser13 p-Cdc37 expression in MOLT-4 and RS4;11 cells treated for 22 h as previously described. Fifty μg of 
protein was blotted to each lane. Antibody to β-actin served as a loading control. Molecular weights are indicated at right. Ctrl, untreated 
cells; 17-AAG, tanespimycin; BZ, bortezomib; CX+BZ, drugs combination.
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Figure 4: Effects of bortezomib/CX-4945 combined treatment on STAT3 phosphorylation and NF-κB activation. A. 
Western blot analysis documenting the time-dependent dephosphorylation of Ser727 and Tyr705 p-STAT3 induced by CX-4945 (5 µM) 
and bortezomib (2.5 nM) either alone or in combination (6 h of pre-treatment with bortezomib, followed by adding of CX-4945 for 6, 16 
and 24 h). Fifty μg of protein was blotted to each lane. Molecular weights are indicated at right. Relative Induction values (Rel.Ind.) were 
obtained by normalizing to STAT-3 density. B. Western blot analysis documenting the time-dependent modulation of NF-κB signaling 
after CX-4945 (5 µM) and bortezomib (2.5 nM) treatment. Cells were treated as previously described and Ser529 and Ser536 p-NF-κB, 
Ser32/36 p-IκBα, and IκBα levels were analyzed. The drug combination induced inhibition of the NF-κB axis in T-ALL cell lines (MOLT-4 
and JURKAT) whereas NF-κB signaling was up-regulated in B-ALL cells (KOPN-8 and RS4;11). Molecular weights are indicated at right. 
C. Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of MOLT-4 and RS4;11cells treated with CX-4945 (5 μM) and 
bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB 
which was revealed by a Cy3-conjugated secondary antibody. In RS4;11 samples combined treatment induces Ser536 p-NF-κB nuclear 
translocation (see white arrows). DAPI (4,6’-diamidino-2-phenylindole, dihydrochloride) was used to label nuclei. Ctrl, untreated cells; 
CX+BZ, drugs combination.
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considered as an oncogenic and anti-apoptotic protein, 
however a growing body of evidence suggests it could 
also mediate cell death, depending on the cell context 
and apoptotic stimulus type [42, 43]. NF-κB can display 
its pro-apoptotic ability when it associates with histone 
deacetylases (HDACs), as in this way NF-κB turns from 
a transcriptional activator of several anti-apoptotic genes 
(Bcl-xL, XIAP, A20) to a transcriptional repressor of 
such genes [44]. To better assess if NF-κB activation, 
observed in RS4;11 cells after bortezomib/CX-4945 
combined treatment, was related to acquisition of pro-
apoptotic functions, we immunoprecipitated NF-κB 
Figure 5: Bortezomib/CX-4945 combined treatment activated NF-κB pro-apoptotic functions in the RS4;11 cell line. 
A. Western blot analysis of immunoprecipitated Ser536 p-NF-κB/HDAC1 complexes in RS4;11 treated for 22 h with CX-4945 (5 µM) and 
bortezomib (2.5 nM) either alone or in combination, as previously described. 500 μg of protein lysates were immunoprecipitated with anti 
NF-κB antibody and then analyzed with the indicated antibodies. B. Western blot analysis documenting the inhibition of XIAP and Bcl-xL 
expression levels induced by a 22 h treatment with CX-4945 (5 µM) and bortezomib (2.5 nM) either alone or in combination. Antibody 
to β-actin served as a loading control. Molecular weights are indicated at right. Ctrl, untreated cells; BZ, bortezomib; CX+BZ, drugs 
combination. C. Viable cell count assay of RS4;11 and MOLT-4 cell lines treated for 16 h with CX-4945 (5 µM) and bortezomib (2.5 nM) 
either alone or in combination (6 h of pre-treatment with bortezomib, followed by adding of CX-4945 for 10 h) and treated with inhibitor 
peptide of NEMO (IKKγ)-binding domain (anti-NEMO) either alone (for 4 h) or in combination with bortezomib/CX-4945 association. In 
RS4;11 cells, anti-NEMO peptide increased the number of viable cells, whereas in MOLT-4, it contributed to enhance the cytotoxic effects 
of the drug combination. Asterisks indicate statistically significant differences (*P < 0.05) between bortezomib/CX-4945 and bortezomib/
CX-4945/anti-NEMO treatments. Ctrl, untreated cells; BZ, bortezomib; CX+BZ, drugs combination; anti-NEMO, inhibitor peptide of 
NEMO (IKKγ)-binding domain.
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and we analyzed, by western blot, its association with 
HDAC1. Figure 5A documents that bortezomib treatment 
induced a small increase in Ser536 p-NF-κB/HDAC1 
complex formation, but adding CX-4945 significantly 
enhanced their association. To verify that p-NF-κB/
HDAC1 complex formation could result in repression 
of NF-κB anti-apoptotic target genes, we analyzed both 
XIAP and Bcl-xL protein expression by western blot. 
In combined treatment samples (16 h) the levels of both 
proteins decreased (Figure 5B). To further document the 
effective contribution of NF-κB activation to the cytotoxic 
effects of bortezomib/CX-4945 treatment in RS4;11 cells, 
we added to the drug combination the inhibitor peptide 
of NEMO (IKKγ)-binding domain (anti-NEMO). We next 
performed a viable cell count assay. Adding anti-NEMO to 
RS4;11 cells increased the number of viable cells, whereas 
in MOLT-4, NF-κB inhibition contributed to enhance 
the cytotoxic effects of the drug combination (Figure 
5C). Taken together these results suggest that, in B-ALL 
cells, but not in T-ALL cells, the bortezomib/CX-4945 
combination triggers NF-κB activation. This activation is 
in a pro-apoptotic direction, in fact inhibition of NF-κB 
dampened the cytotoxic effects of the combined treatment.
Bortezomib/CX-4945 combined treatment is 
effective in T- and B- ALL blasts
To better assess the efficacy of the bortezomib/
CX-4945 combined treatment as a potential therapeutic 
strategy in T- and B-ALL, we studied some pediatric 
T-ALL and B-ALL patient samples isolated from the 
bone marrow. Cells were incubated for a total of 46 h 
with either single drugs or a combination (6 h of pre-
treatment with bortezomib, followed by adding CX-
4945 for 40 h) of the two drugs at a constant ratio of 
1:1000 (bortezomib:CX). Cell viability rates and C.I.s 
were calculated. The combined treatment displayed a 
good synergism, as indicated by the C.I.s (Figure 6A). 
Involvement of apoptosis, ER stress/UPR signaling, 
and NF-κB activation were assessed by western blot 
analysis after 16 h of treatment. Drug combination 
induced cleavage of both PARP and caspase-8 as well 
as a concomitant reduction of the proapoptotic Bcl-
xL, both in T- and in B-ALL lymphoblasts (Figure 6B). 
Consistent with findings obtained in ALL cell lines, the 
combined treatment markedly down-regulated BIP/Grp78 
protein levels, except for one B-ALL patient. In T-ALL 
patient lymphoblasts, the combined treatment down-
modulated Ser529 p-NF-κB and was able to dampen the 
increase in Ser536 p-NF-κB, and Ser32/36 p-IκBα levels 
caused by bortezomib. Very interestingly, also in B-ALL 
primary cells, as observed in B-ALL cell lines, the drug 
combination induced Ser536 p-NF-κB and a concomitant 
p-IκBα increase (Figure 6B).
DISCUSSION
Several lines of evidence have recently indicated 
that CK2 represents a pivotal molecule both regulating 
hematopoiesis-associated signaling cascades and driving 
the growth of different blood tumors. In fact CK2 plays 
a critical triggering role in several survival pathways 
including the PI3K/Akt/mTOR, WNT, NF-κB, and JAK-
STAT networks, both in lymphoid and myeloid tumors 
[28, 45]. Preclinical evidence from studies testing the 
clinical-stage CK2 inhibitor CX-4945 in hematological 
malignancies, have demonstrated that there is a strong 
rationale for targeting CK2 in blood cancers and supported 
the initiation of clinical trials using CK2 antagonists. 
Previously, we provided evidence, in pre-clinical settings 
of T-ALL, that CX-4945 could induce apoptotic cell 
death through down-modulation of the UPR signaling 
pathway. Intriguingly, we have also demonstrated that 
a combination of CX-4945 with the ER stress inducer, 
thapsigargin, was synergistic in killing T-ALL cells [26]. 
ER stress and UPR pathways are activated in a wide 
variety of tumor types and have been demonstrated to be 
essential for tumor cell survival [46]. Although ER stress 
represents only one of the several processes associated 
with bortezomib-induced cell death [47], it is conceivable 
that it could indeed represent the key component [48, 49]. 
Acquisition of a more powerful UPR, due to deregulated 
expression of several heat shock protein family members, 
has been strongly associated with bortezomib resistance 
in a wide range of B-cell malignancies [38, 50, 51]. In the 
present study, we documented, in a panel of T- and B-ALL 
cell lines and primary samples, that bortezomib-dependent 
pro-apoptotic effects were significantly amplified by 
CX-4945 mediated inhibition of CK2. Apoptosis was 
accompanied by inhibition of UPR signaling, as evidenced 
by down-regulation of pro-survival ER chaperon BIP/
Grp78. BIP/Grp78, when expressed at high levels, is 
involved in aggressive phenotype and chemoresistance in 
both proliferating and dormant cancer cells and it has been 
strongly correlated to resistance to bortezomib [40, 52-
54]. We described that the combined treatment provoked 
BIP/Grp78 depletion, via decrease of the chaperoning 
activity of Hsp90. This is in agreement with findings 
obtained in MCL settings [40] and may explain the 
efficacy of heat shock protein inhibitors in combination 
with bortezomib [55-57]. Our observations indicated that 
dephosphorylation of co-chaperone Cdc37 at Ser13, which 
is CX-4945 mediated, seems to be the driving force for 
the impairment of BIP/Hsp90/Cdc37 complex, similarly 
to the findings of others for IRE1α [33]. Bortezomib/CX-
4945 combination also induced ER stress more efficiently 
than single treatments, as demonstrated by up-regulation 
of IRE1α, CHOP, p-PERK and p-EIF2α expression 
levels. Thus, we hypothesized that the adding of CX-
4945 after a previous bortezomib exposure, prevents 
leukemic cells to adequately cope with the stronger 
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ER stress by properly activating UPR signaling. This 
pharmacological manipulation of ER stress is the base 
of the well documented efficacy of ER stress aggravators 
(ERSAs) (thapsigargin, tunicamycin, nelfinavir, etc) and 
has become an attractive approach for cancer therapeutic 
purposes [49, 51, 58]. We also demonstrated that the 
Figure 6: The Bortezomib/CX-4945 combined treatment is cytotoxic to primary lymphoblasts from T- and B-ALL 
patients, affects ER stress/UPR signaling and activates NF-κB pro-apoptotic functions. A. MTT assays performed 
on primary cells from 3 pediatric T-ALL and 3 pediatric B-ALL patients treated for 46 h total with either one drug alone or with a 
combination (6 h of pre-treatment with bortezomib, followed by adding of CX-4945 for 40 h) of the two drugs at a constant ratio of 1:1000 
(bortezomib:CX-4945). The combined treatment resulted in a strong synergism (CIs 0.1-0.3), synergism (CIs 0.3-0.7) or moderate/slight 
synergism (CIs 0.7-0.9); data are representative of three independent experiments, bars, s.d., CX, CX-4945; BZ, bortezomib. B. Western 
blot analysis of proteins extracted from two of T-ALL and two of B-ALL patient lymphoblasts, documenting a. the induction of apoptosis 
confirmed by cleavage of PARP, activation of caspase-8, and inhibition of Bcl-xL levels b. UPR inhibition, confirmed by BIP/Grp78 
depletion, except for ALL-B#2 c. NF-κB pro-apoptotic activation, documented by induction of Ser536 p-NF-κB and Ser32/36 p-IκBα. 
Fifty μg of protein was blotted to each lane. Antibody to β-actin served as a loading control. Molecular weights are indicated at right. Ctrl, 
untreated cells; CX, CX-4945; BZ, bortezomib; CX+BZ, drugs combination.
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bortezomib/CX-4945 combination was able to trigger NF-
κB activation in B-ALL models but not in T-ALL ones. In 
particular, in the RS4;11 cell line, we observed that this 
activation is in pro-apoptotic sense. The forming of the 
p-NF-κB/HDAC1 complex and the down-modulation of 
antiapoptotic XIAP and Bcl-xL levels may suggest the 
shift of NF-κB from a transcriptional activator of anti-
apoptotic genes to a transcriptional repressor of them. We 
do not have direct evidence that reduced expression of 
these genes is the result of transcriptional repression by 
Ser536 p-NF-κB/HDAC1 complex, an issue that we are 
now investigating. Moreover, the reduction of cytotoxic 
effects of the combined treatment in RS4;11 cells after 
an anti-NEMO peptide treatment, further indicated that 
the drug combination was able to unleash NF-κB pro-
apoptotic ability. It has been assumed that cancer cells 
activate NF-κB signaling in response to chemotherapy 
as a pro-survival strategy [59]. In contrast, a growing 
body of evidence indicates that NF-κB also has a tumor-
suppressive function, which is heavily dependent on the 
stimuli and cell-type context [43, 60, 61]. It should be 
underlined that, despite its power to inhibit proteasome 
degradation of NF-κB inhibitor IκBα, bortezomib is 
already known to activate NF-κB signaling in ALLs 
and IκBα degradation has been described as a calpain-
dependent event [62, 63]. Our observations indicated that 
CK2 inhibition could facilitate this bortezomib intrinsic 
ability, in B-ALL models. Very recently it has been 
discovered that phosphorylation of a highly conserved 
tyrosine residue, Tyr 57, in histone H2A was mediated 
by the unsuspected tyrosine kinase activity of CK2 and 
plays a critical role in transcriptional regulation. In fact, 
either inhibition of CK2 or Tyr 57 mutation impaired 
transcriptional elongation [64]. By western blotting, we 
analyzed phospho-tyrosine levels in histones isolated from 
RS4;11 cells treated with single drugs or with bortezomib/
CX-4945 combination. We observed that the combined 
treatment was able to reduce phosphorylated tyrosine 
level in a protein band corresponding to histones H2A, 
more than single treatments (Supplementary Figure S2). 
This finding could explain the transcriptional repression of 
the anti-apoptotic genes normally activated by NF-κB in 
B-ALL models. At present, we do not have an explanation 
for the different behavior of NF-κB in T-ALL models. 
It has been demonstrated, in AML settings, that CX-
4945 mediated CK2 inhibition caused a p53-dependent 
apoptosis [65]. T-ALL cell lines used in this study are p53 
mutated, conversely B-ALL are p53 wild type but we did 
not observe a significant modulation of p53 active form 
after any drug treatments (data not shown).
Finally, we demonstrated a synergistic effect of 
bortezomib/CX-4945 combination also in primary cells 
from T- and B-ALL patients. Apoptotic cell death occurred 
through inhibition of UPR pathway and, as in the case 
of cell lines, while in B-ALL patients we observed NF-
κB signaling activation, in T-ALL patients this did not 
occur. These findings are consistent with previous results 
describing a possible involvement of NF-κB as pro-
apoptotic mediator in a panel of B-ALL cell lines, primary 
samples, and xenograft mouse models treated with a 
combination of bortezomib and HDAC inhibitors [22]. 
It is noteworthy that we have focused our observations 
on primary cells from a subset of immature B-ALL 
patients. However, when we tested the bortezomib/CX-
4945 combination on a subset of mature B-ALL patients, 
in front of no NF-κB signaling activation, we have not 
observed any synergistic apoptotic effects (data not 
shown). Further experiments are necessary to establish if 
activation of NF-κB pro-apoptotic ability, via p-NF-κB/
HDAC1 complex formation, plays a role in bortezomib/
CX-4945 cytotoxicity in all B-ALL or only in some 
subsets of B-ALL. 
In conclusion, in this work we provide evidence that 
inhibition of CK2 could enhance bortezomib-mediated cell 
death of ALL cells. Mechanisms involved in this synergism 
are multiple and each could represent an “Achilles heel” 
of cancer cell. Adding CX-4945 to bortezomib treatment 
resulted in UPR pathway inhibition through deletion of 
pro-survival ER chaperon BIP/Grp78 and, only in B-ALL 
models, the combination released the NF-κB pro-apoptotic 
ability. It is conceivable that the use of CK2 inhibitors in 
bortezomib-based combination protocols in ALL settings, 
could be a therapeutic opportunity, able to counteract the 
occurrence of bortezomib-resistant clones.
MATERIALS AND METHODS
Materials
Bortezomib, CX-4945, and tanespimycin (17-AAG) 
were kindly provided by Selleck Chemicals (Houston, TX, 
USA). Antibody to caspase-4 and Ser529 p-NF-κB were 
from Abcam (Cambridge, UK). Cdc37 antibody was from 
BD Biosciences (San Jose, CA, USA). All of the other 
primary and secondary antibodies for western blotting 
and flow cytometry analyses were from Cell Signaling 
Technology (Danvers, MA, USA). Cell Proliferation Kit 
I (MTT) was purchased from Roche Applied Science 
(Penzberg, Germany). NEMO (IKKγ)-binding domain 
inhibitor peptide was obtained from Imgenex (Novus 
Biologicals, Littleton, CO, USA). 
Cell culture and primary T-and B- ALL samples
T-ALL (MOLT-4, JURKAT, drug-resistant CCRF-
CEM or CEM-R) and B-ALL (KOPN-8, RS4;11, 
NALM-6) cell lines were grown in RPMI 1640 medium, 
supplemented with either 10% or 20% heat-inactivated 
fetal bovine serum (FBS), depending on the cell line. 
Patient samples were obtained after informed consent 
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according to Institutional guidelines and isolated by Ficoll-
Paque (Amersham Biosciences AB, Uppsala, Sweden). 
T-ALL and B-ALL lymphoblasts were cultured in RPMI 




Diphenyltetrazolium Bromide) assays were performed 
as previously reported [66]. For drug-combination 
experiments, a combination index (CI) number was 
calculated using the CalcuSyn software (BioSoft, 
Cambridge, UK) based on the Chou and Talalay method 
[67]. CI values between 0.1-0.9 define different grades of 
synergism: values between 0.9-1.1 are additive, whereas 
values  >  1.1 are antagonistic. 
Annexin V-fluorescein isothiocyanate (FITC)/
propidium iodide (PI) staining
To determine the extent of apoptosis induction 
after drug treatment, flow cytometric analysis of Annexin 
V-FITC/PI-stained samples was performed as previously 
reported [68]. All the flow cytometric analyses were 
performed on an FC500 flow cytometer (Beckman, Miami, 
FL, USA), with the appropriate software (CXP, Beckman).
Flow cytometry analysis of JC-1 dye
Assessment of apoptosis induction was also 
obtained by detection of mitochondrial membrane 
potential using the 5,59,6,69, tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolyl carbocyanin iodide dye (JC-1) 
(Molecular Probes, Eugene, OR, USA) according to the 
manufacturer instructions.
Western blot analysis and immunoprecipitation
Western blot analysis and immunoprecipitation were 
performed as previously detailed [69]. Cells were lysed 
using the M-PER Mammalian Protein Extraction Reagent, 
supplemented with the Protease and Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific Inc., Rockford, IL, 
USA). BIP/Grp78 and HDAC immunoprecipitation 
was carried out using Pierce Classic IP Kit (Thermo 
Fisher Scientific Inc., Rockford, IL, USA), following the 
manufacturer instructions. Densitometry scanning of the 
bands were performed using a Chemidoc 810 Imager with 
the appropriate software (UVP, Upland, CA, USA).
Histone isolation
Cells were lysed in PBS containing 0.5% Triton 
X100 (TEB) supplemented with the Protease and 
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific 
Inc., Rockford, IL, USA). After 10 min lysis on ice with 
gentle stirring, cells were centrifuged to spin down the 
nuclei. Nuclei pellet was washed in TEB and resuspended 
in 0.2 N HCl over night at 4°C to extract histones. After 
acid extraction, samples were centrifuged to remove 
debris. Supernatant containing histone proteins was 
mixed with acetone and incubated overnight at -20°C. The 
precipitated material was collected by microcentrifugation 
and air-dried. The acid-soluble histone fraction was 
dissolved in water and quantified for western blot analysis. 
Histones were immunoblotted with anti p-Tyr-100 
antibody.
Fluorescence immunocytochemistry
Fluorescence immunocytochemistry analysis were 
performed as previously described [70]. Cells were labeled 
with an antibody to Ser536 p-NF-κB, which was then 
detected by a Cy3-conjugated secondary antibody. DAPI 
(4,6’-diamidino-2-phenylindole, dihydrochloride) was 
used to counterstain nuclei. Images were taken under a 
Zeiss Axio Imager.Z1 microscope (Zeiss, Jena, Germany), 
with 40x/NA 0.75 optics, coupled to a computer-driven 
Zeiss AxioCAM digital camera (MRm), using the Zeiss 
AxioVision (version 4.5) software.
Statistical analysis
The data are presented as the mean values from 
three separate experiments±s.d. Statistical analyses were 
performed using Student’s t test at a significance level of 
p  <  0.05 (GraphPad Prism Software).
ACKNOWLEDGMENTS
This work was partially supported by a grant from 
Fondazione del Monte di Bologna e Ravenna to A.M.M. 
The authors would like to thank Selleck Chemicals 
for generously providing CX-4945, bortezomib, and 
tanespimycin (17-AAG).
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
Oncotarget1337www.impactjournals.com/oncotarget
REFERENCES
1. Pui CH, Robison LL and Look AT. Acute lymphoblastic 
leukaemia. Lancet. 2008; 371:1030-1043.
2. Graux C. Biology of acute lymphoblastic leukemia (ALL): 
clinical and therapeutic relevance. Transf Apher Sci. 2011; 
44:183-189.
3. Harned TM and Gaynon P. Relapsed acute lymphoblastic 
leukemia: current status and future opportunities. Curr 
Oncol Reps. 2008; 10:453-458.
4. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, 
Tubergen DG, Steinherz PG and Trigg ME. Survival after 
relapse in childhood acute lymphoblastic leukemia: impact 
of site and time to first relapse—the Children’s Cancer 
Group Experience. Cancer. 1998; 82:1387-1395.
5. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow 
MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin 
IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH, 
Medical Research Council of the United Kingdom Adult 
ALLWP and Eastern Cooperative Oncology G. Outcome 
of 609 adults after relapse of acute lymphoblastic leukemia 
(ALL); an MRC UKALL12/ECOG 2993 study. Blood. 
2007; 109:944-950.
6. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz 
E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS 
and Loh ML. Outcome of patients treated for relapsed or 
refractory acute lymphoblastic leukemia: a Therapeutic 
Advances in Childhood Leukemia Consortium study. J Clin 
Oncol. 2010; 28:648-654.
7. Pui CH and Evans WE. Treatment of acute lymphoblastic 
leukemia. N Engl J Med. 2006; 354:166-178.
8. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, 
Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, 
Leighton J, Liang CY, Lostritto RT, McGuinn WD, Morse 
DE, Rahman A, et al. Approval summary for bortezomib 
for injection in the treatment of multiple myeloma. Clin 
Cancer Res. 2004; 10:3954-3964.
9. Kane RC, Farrell AT, Sridhara R and Pazdur R. United 
States Food and Drug Administration approval summary: 
bortezomib for the treatment of progressive multiple 
myeloma after one prior therapy. Clin Cancer Res. 2006; 
12:2955-2960.
10. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice 
R and Pazdur R. Bortezomib for the treatment of mantle cell 
lymphoma. Clin Cancer Res. 2007; 13:5291-5294.
11. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, 
Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, 
Wright J and Kantarjian H. Phase I study of bortezomib in 
refractory or relapsed acute leukemias. Clin Cancer Res. 
2004; 10:3371-3376.
12. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, 
Adamson PC, Ingle AM, Wright J, Brockman AH, Paton 
M and Blaney SM. A phase 1 study of the proteasome 
inhibitor bortezomib in pediatric patients with refractory 
leukemia: a Children’s Oncology Group study. Clin Cancer 
Res. 2007; 13:1516-1522.
13. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, 
Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J 
and Smith MA. Initial testing (stage 1) of the proteasome 
inhibitor bortezomib by the pediatric preclinical testing 
program. Pediatr Blood Cancer. 2008; 50:37-45.
14. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, 
Eckroth E, Malvar J, Bostrom BC, Therapeutic Advances 
in Childhood L and Lymphoma C. Bortezomib with 
chemotherapy is highly active in advanced B-precursor 
acute lymphoblastic leukemia: Therapeutic Advances in 
Childhood Leukemia & Lymphoma (TACL) Study. Blood. 
2012; 120:285-290.
15. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, 
Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-
Delgado I, Baer MR, Holleran JL, Egorin MJ and Grant S. 
Phase I study of vorinostat in combination with bortezomib 
for relapsed and refractory multiple myeloma. Clin Cancer 
Res. 2009; 15:5250-5257.
16. Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, 
Moynihan T, Croghan G, Markovic SN, Bible KC, Qin 
R, Tan A, Molina J, Kaufmann SH, Erlichman C and 
Adjei AA. Phase 1 study of sorafenib in combination with 
bortezomib in patients with advanced malignancies. Invest 
New Drugs. 2013; 31:1201-1206.
17. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema 
NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, 
Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond 
CA, Schaaf LJ, et al. Phase II study of flavopiridol in 
relapsed chronic lymphocytic leukemia demonstrating high 
response rates in genetically high-risk disease. J Clin Oncol. 
2009; 27:6012-6018.
18. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, 
Campo E and Colomer D. The novel HSP90 inhibitor IPI-
504 synergizes with bortezomib in mantle cell lymphoma 
cells by targeting both NF-kappaB signaling and unfolded 
protein response and leading to increased mitochondrial 
apoptosis. Blood. 2007; 110:478a-478a.
19. Wright JJ. Combination therapy of bortezomib with novel 
targeted agents: an emerging treatment strategy. Clin 
Cancer Res. 2010; 16:4094-4104.
20. Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa 
H, Chiba S and Furukawa Y. Proteasome inhibitors 
exert cytotoxicity and increase chemosensitivity via 
transcriptional repression of Notch1 in T-cell acute 
lymphoblastic leukemia. Leukemia. 2014; 28:1216-1226.
21. Huang C, Hu X, Wang L, Lu S, Cheng H, Song X, Wang J 
and Yang J. Bortezomib suppresses the growth of leukemia 
cells with Notch1 overexpression in vivo and in vitro. 
Cancer Chemother Pharmacol. 2012; 70:801-809.
22. Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G, 
Prada J, von Stackelberg A, Seeger K and Shalapour S. 
Synergistic activity of bortezomib and HDACi in preclinical 
models of B-cell precursor acute lymphoblastic leukemia 
Oncotarget1338www.impactjournals.com/oncotarget
via modulation of p53, PI3K/AKT, and NF-kappaB. Clin 
Cancer Res. 2013; 19:1445-1457.
23. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, 
Jr., Lee KP and Boise LH. Proteasome inhibitors induce 
a terminal unfolded protein response in multiple myeloma 
cells. Blood. 2006; 107:4907-4916.
24. Kuznetsov JN, Leclerc GJ, Leclerc GM and Barredo JC. 
AMPK and Akt determine apoptotic cell death following 
perturbations of one-carbon metabolism by regulating ER 
stress in acute lymphoblastic leukemia. Mol Cancer Ther. 
2011; 10:437-447.
25. DeSalvo J, Kuznetsov JN, Du J, Leclerc GM, Leclerc GJ, 
Lampidis TJ and Barredo JC. Inhibition of Akt potentiates 
2-DG-induced apoptosis via downregulation of UPR in 
acute lymphoblastic leukemia. Mol Cancer Res. 2012; 
10:969-978.
26. Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti 
A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti 
C, Melchionda F, Pession A, Bertaina A, Locatelli F, 
McCubrey JA, Cappellini A, Barata JT, et al. Cytotoxic 
activity of the casein kinase 2 inhibitor CX-4945 against 
T-cell acute lymphoblastic leukemia: targeting the unfolded 
protein response signaling. Leukemia. 2014; 28:543-553.
27. Leclerc GM, Leclerc GJ, Kuznetsov JN, DeSalvo J 
and Barredo JC. Metformin induces apoptosis through 
AMPK-dependent inhibition of UPR signaling in ALL 
lymphoblasts. PloS One. 2013; 8:e74420.
28. Ruzzene M and Pinna LA. Addiction to protein kinase CK2: 
a common denominator of diverse cancer cells? Biochim 
Biophys Acta. 2010; 1804:499-504.
29. Romieu-Mourez R, Landesman-Bollag E, Seldin DC 
and Sonenshein GE. Protein kinase CK2 promotes 
aberrant activation of nuclear factor-kappaB, transformed 
phenotype, and survival of breast cancer cells. Cancer Res. 
2002; 62:6770-6778.
30. Kato T, Jr., Delhase M, Hoffmann A and Karin M. CK2 Is 
a C-Terminal IkappaB Kinase Responsible for NF-kappaB 
Activation during the UV Response. Mol Cell. 2003; 
12:829-839.
31. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, 
Brustolon F, Pinna LA and Ruzzene M. Protein kinase 
CK2 phosphorylates and upregulates Akt/PKB. Cell Death 
Differ. 2005; 12:668-677.
32. Hessenauer A, Schneider CC, Gotz C and Montenarh 
M. CK2 inhibition induces apoptosis via the ER stress 
response. Cell Signal. 2011; 23:145-151.
33. Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, 
Cabrelle A, Ave E, Zaffino F, Di Maira G, Ruzzene M, 
Adami F, Zambello R, Pitari MR, Tassone P, Pinna LA, 
Gurrieri C, et al. Protein kinase CK2 protects multiple 
myeloma cells from ER stress-induced apoptosis and from 
the cytotoxic effect of HSP90 inhibition through regulation 
of the unfolded protein response. Clin Cancer Res. 2012; 
18:1888-1900.
34. Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, 
Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, Cabrelle 
A, Marino F, Zambello R, Trentin L, Adami F, Gurrieri C, 
Semenzato G, et al. Protein kinase CK2 inhibition down 
modulates the NF-kappaB and STAT3 survival pathways, 
enhances the cellular proteotoxic stress and synergistically 
boosts the cytotoxic effect of bortezomib on multiple 
myeloma and mantle cell lymphoma cells. PloS one. 2013; 
8:e75280.
35. Hosoi T, Korematsu K, Horie N, Suezawa T, Okuma Y, 
Nomura Y and Ozawa K. Inhibition of casein kinase 2 
modulates XBP1-GRP78 arm of unfolded protein responses 
in cultured glial cells. PloS one. 2012; 7:e40144.
36. Vaeteewoottacharn K, Kariya R, Matsuda K, Taura M, 
Wongkham C, Wongkham S and Okada S. Perturbation of 
proteasome function by bortezomib leading to ER stress-
induced apoptotic cell death in cholangiocarcinoma. J 
Cancer Res Clin Oncol. 2013; 139:1551-1562.
37. Vander Heiden MG, Chandel NS, Williamson EK, 
Schumacker PT and Thompson CB. Bcl-xL regulates 
the membrane potential and volume homeostasis of 
mitochondria. Cell. 1997; 91:627-637.
38. Mozos A, Roue G, Lopez-Guillermo A, Jares P, Campo 
E, Colomer D and Martinez A. The expression of the 
endoplasmic reticulum stress sensor BiP/GRP78 predicts 
response to chemotherapy and determines the efficacy of 
proteasome inhibitors in diffuse large b-cell lymphoma. Am 
J Pathol. 2011; 179:2601-2610.
39. Walter P and Ron D. The unfolded protein response: from 
stress pathway to homeostatic regulation. Science. 2011; 
334:1081-1086.
40. Roue G, Perez-Galan P, Mozos A, Lopez-Guerra M, 
Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant 
E, Campo E and Colomer D. The Hsp90 inhibitor IPI-504 
overcomes bortezomib resistance in mantle cell lymphoma 
in vitro and in vivo by down-regulation of the prosurvival 
ER chaperone BiP/Grp78. Blood. 2011; 117:1270-1279.
41. Piazza F, Manni S and Semenzato G. Novel players in 
multiple myeloma pathogenesis: role of protein kinases 
CK2 and GSK3. Leuk Res. 2013; 37:221-227.
42. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, 
Droge W and Schmitz ML. The pro- or anti-apoptotic 
function of NF-kappaB is determined by the nature of the 
apoptotic stimulus. Eur J Biochem. 2000; 267:3828-3835.
43. Radhakrishnan SK and Kamalakaran S. Pro-apoptotic role 
of NF-kappaB: implications for cancer therapy. Biochim 
Biophys Acta. 2006; 1766:53-62.
44. Campbell KJ, Rocha S and Perkins ND. Active repression 
of antiapoptotic gene expression by RelA(p65) NF-kappa B. 
Mol Cell. 2004; 13:853-865.
45. Duncan JS and Litchfield DW. Too much of a good 
thing: the role of protein kinase CK2 in tumorigenesis 
and prospects for therapeutic inhibition of CK2. Biochim 
Biophys Acta. 2008; 1784:33-47.
Oncotarget1339www.impactjournals.com/oncotarget
46. Li X, Zhang K and Li Z. Unfolded protein response in 
cancer: the physician’s perspective. J Hematol Oncol. 2011; 
4:8.
47. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, 
Chen TC, Louie SG, Petasis NA and Schonthal AH. 
Aggravated endoplasmic reticulum stress as a basis for 
enhanced glioblastoma cell killing by bortezomib in 
combination with celecoxib or its non-coxib analogue, 
2,5-dimethyl-celecoxib. Cancer Res. 2008; 68:843-851.
48. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, 
Koong AC and Koumenis C. Preferential cytotoxicity of 
bortezomib toward hypoxic tumor cells via overactivation 
of endoplasmic reticulum stress pathways. Cancer Res. 
2008; 68:9323-9330.
49. Schonthal AH. Pharmacological targeting of endoplasmic 
reticulum stress signaling in cancer. Biochem Pharmacol. 
2013; 85:653-666.
50. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai 
YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima 
T, Mitsiades C, Munshi NC, Chauhan D and Anderson KC. 
Gene expression analysis of B-lymphoma cells resistant and 
sensitive to bortezomib. Br J Haematol. 2006; 134:145-156.
51. Davenport EL, Moore HE, Dunlop AS, Sharp SY, 
Workman P, Morgan GJ and Davies FE. Heat shock protein 
inhibition is associated with activation of the unfolded 
protein response pathway in myeloma plasma cells. Blood. 
2007; 110:2641-2649.
52. Li J and Lee AS. Stress induction of GRP78/BiP and its role 
in cancer. Curr Mol Med. 2006; 6:45-54.
53. Lee AS. GRP78 induction in cancer: therapeutic and 
prognostic implications. Cancer Res. 2007; 67:3496-3499.
54. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye 
R, Wang M, Pen L, Dubeau L, Groshen S, Hofman FM and 
Lee AS. Critical role of the stress chaperone GRP78/BiP 
in tumor proliferation, survival, and tumor angiogenesis in 
transgene-induced mammary tumor development. Cancer 
Res. 2008; 68:498-505.
55. Kapoor P, Ramakrishnan V and Rajkumar SV. Bortezomib 
combination therapy in multiple myeloma. Semin Hematol. 
2012; 49:228-242.
56. Bruning A and Juckstock J. Misfolded proteins: from little 
villains to little helpers in the fight against cancer. Front 
Oncol. 2015; 5:47.
57. Hamouda MA, Belhacene N, Puissant A, Colosetti P, Robert 
G, Jacquel A, Mari B, Auberger P and Luciano F. The 
small heat shock protein B8 (HSPB8) confers resistance to 
bortezomib by promoting autophagic removal of misfolded 
proteins in multiple myeloma cells. Oncotarget. 2014; 
5:6252-6266. doi: 10.18632/oncotarget.2193.
58. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, 
Chanan-Khan AA and Anderson KC. Inhibition of heat 
shock protein 90 (HSP90) as a therapeutic strategy for the 
treatment of myeloma and other cancers. Br J Haematol. 
2011; 152:367-379.
59. Perkins ND. Integrating cell-signalling pathways with NF-
kappaB and IKK function. Nat Rev Mol Cell Biol. 2007; 
8:49-62.
60. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden 
JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC 
and Lowe SW. Control of the senescence-associated 
secretory phenotype by NF-kappaB promotes senescence 
and enhances chemosensitivity. Genes Dev. 2011; 25:2125-
2136.
61. Jing H, Kase J, Dorr JR, Milanovic M, Lenze D, Grau M, 
Beuster G, Ji S, Reimann M, Lenz P, Hummel M, Dorken 
B, Lenz G, Scheidereit C, Schmitt CA and Lee S. Opposing 
roles of NF-kappaB in anti-cancer treatment outcome 
unveiled by cross-species investigations. Genes Dev. 2011; 
25:2137-2146.
62. Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR and Sun 
SY. Proteasome inhibitor PS-341 (bortezomib) induces 
calpain-dependent IkappaB(alpha) degradation. J Biol 
Chem. 2010; 285:16096-16104..
63. Riz I, Zweier-Renn LA, Toma I, Hawley TS and Hawley 
RG. Apoptotic role of IKK in T-ALL therapeutic response. 
Mol Cancer Res. 2011; 9:979-984.
64. Basnet H, Su XB, Tan Y, Meisenhelder J, Merkurjev D, 
Ohgi KA, Hunter T, Pillus L and Rosenfeld MG. Tyrosine 
phosphorylation of histone H2A by CK2 regulates 
transcriptional elongation. Nature. 2014; 516:267-271.
65. Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, 
Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, 
Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato 
G and Piazza F. Inhibition of protein kinase CK2 with the 
clinical-grade small ATP-competitive compound CX-4945 
or by RNA interference unveils its role in acute myeloid 
leukemia cell survival, p53-dependent apoptosis and 
daunorubicin-induced cytotoxicity. J Hematol Oncol. 2013; 
6:78.
66. Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, 
Gladkich J, Nwaeburu CC, Mattern J, Mollenhauer M, 
Ruckert F, Zach S, Haberkorn U, Gross W, Schonsiegel 
F, Bazhin AV, et al. Inhibition of glucose turnover by 
3-bromopyruvate counteracts pancreatic cancer stem cell 
features and sensitizes cells to gemcitabine. Oncotarget. 
2014; 5:5177-5189. doi: 10.18632/oncotarget.2120.
67. Chou TC and Talalay P. Quantitative analysis of dose-effect 
relationships: the combined effects of multiple drugs or 
enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.
68. Tang J, Zhu J, Yu Y, Zhang Z, Chen G, Zhou X, Qiao 
C, Hou T and Mao X. A virtual screen identified C96 
as a novel inhibitor of phosphatidylinositol 3-kinase 
that displays potent preclinical activity against multiple 
myeloma in vitro and in vivo. Oncotarget. 2014; 5:3836-
3848. doi: 10.18632/oncotarget.1657.
69. Lonetti A, Cappellini A, Sparta AM, Chiarini F, Buontempo 
F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA and 
Martelli AM. PI3K pan-inhibition impairs more efficiently 
proliferation and survival of T-cell acute lymphoblastic 
Oncotarget1340www.impactjournals.com/oncotarget
leukemia cell lines when compared to isoform-selective 
PI3K inhibitors. Oncotarget. 2015; 6:10399-10414. doi: 
10.18632/oncotarget.3295.
70. Buontempo F, Chiarini F, Bressanin D, Tabellini G, 
Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA 
and Martelli AM. Activity of the selective IkappaB kinase 
inhibitor BMS-345541 against T-cell acute lymphoblastic 
leukemia: involvement of FOXO3a. Cell Cycle. 2012; 
11:2467-2475.
